Literature DB >> 7738712

Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.

K K Krishnadath1, H W Tilanus, M van Blankenstein, F T Bosman, A H Mulder.   

Abstract

Accumulation of p53 protein was determined by immunohistochemistry in archival material of biopsy specimens from 102 patients with Barrett's oesophagus with different grades of dysplasia, in 24 oesophageal adenocarcinomas associated with Barrett's oesophagus, and in 23 cases of metaplastic epithelium adjacent to these carcinomas. Immunostaining for the p53 protein was found in 23/102 (23 per cent) cases of the Barrett's oesophagus biopsies and in 12/23 (52 per cent) cases of Barrett's oesophagus adjacent to adenocarcinoma. Significant correlations were found between the grade of dysplasia and p53 immunoreactivity in both Barrett's biopsies without adenocarcinoma (P < 0.001) and Barrett's oesophagus adjacent to adenocarcinoma (P < 0.05). In the adenocarcinomas, intense nuclear immunohistochemical staining for p53 was diffusely or focally present in 20/24 (83 per cent) of the specimens. In Barrett's oesophagus, p53 is a progression marker with high expression in high-grade dysplasia (89 per cent) and adenocarcinoma (83 per cent).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738712     DOI: 10.1002/path.1711750204

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

Review 4.  Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy.

Authors:  S R DeMeester; T R DeMeester
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

5.  Predicting Neoplastic Progression in Barrett's Esophagus.

Authors:  Jean S Wang; Marcia I Canto
Journal:  Ann Gastroentol Hepatol       Date:  2010-06

6.  Observer variation in the diagnosis of superficial oesophageal adenocarcinoma.

Authors:  A H Ormsby; R E Petras; W H Henricks; T W Rice; L A Rybicki; J E Richter; J R Goldblum
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

7.  p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.

Authors:  Mamoun Younes; Keith Brown; Gregory Y Lauwers; Gulchin Ergun; Frank Meriano; A Carl Schmulen; Alberto Barroso; Atilla Ertan
Journal:  Histopathology       Date:  2017-04-11       Impact factor: 5.087

8.  Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.

Authors:  P A Hall; A C Woodman; S J Campbell; N A Shepherd
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 9.  Barrett's esophagus: model of neoplastic progression.

Authors:  Stig Ramel
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

10.  Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus.

Authors:  C J Buskens; A Sivula; B P van Rees; C Haglund; G J A Offerhaus; J J B van Lanschot; A Ristimäki
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.